Oncology

The combination of tislelizumab and chemotherapy demonstrated a statistically significant improvement in progression-free survival.

Belzutifan is indicated for the treatment of adult patients with von Hippel-Lindau disease who require therapy for associated renal cell carcinoma, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors.

Myriam Mendila, MD, chief medical officer and global head of medical affairs at Novartis Oncology, discusses how the ASCEMBL study data may impact treatment strategies and approaches for patients with chronic myeloid leukemia.

Following the success of ibrutinib, second-generation BTK inhibitors have shown even better outcomes with fewer toxicities.

The body of research around acalabrutinib is becoming quite advanced, allowing clinicians to feel confident when treating patients.

Myriam Mendila, MD, chief medical officer and global head of medical affairs at Novartis Oncology, discusses how asciminib has impacted the treatment landscape for chronic myeloid leukemia.

New data are being presented at ASH 2021 regarding the durable efficacy of acalabrutinib in chronic lymphocytic leukemia.

The multicenter phase 3 study randomized patients with R/R CLL 1:1 to receive acalabrutinib 100 mg orally twice daily or investigator’s choice of idelalisib plus rituximab or bendamustine plus rituximab until disease progression or unacceptable toxicity.

Myriam Mendila, MD, chief medical officer and global head of medical affairs at Novartis Oncology, discusses new longer-term efficacy and safety data from the pivotal phase 3 ASCEMBL study.

According to the trial results, these responses appear durable, with a target dose-dependent increase in overall response rate without any increase in the rate of cytokine release syndrome.

In a phase 1b trial, the combination therapy of acalabrutinib, venetoclax, and rituximab had a 100% clinical response rate and was well-tolerated in patients with treatment-naïve mantle cell lymphoma.

Fast track application is based on positive data in HER2 exon 20 insertion mutations in previously treated patients.

FoundationOne CDx is a next-generation sequencing based in vitro diagnostic device for detection, insertion and deletion alterations, and copy number alterations in 324 genes and select gene rearrangements.

Pembrolizumab is the first anti-PD-1/anti-PD-L1 therapy to demonstrate a recurrence-free survival benefit in the adjuvant setting for melanoma.

Daratumumab continued to demonstrate deep and durable responses, including improvements to stringent complete response (sCR) rates and minimal residual disease (MRD)-negativity.

Axicabtagene ciloleucel (Yescarta) was the first CAR T-cell immunotherapy to be approved for relapsed or refractory large B-cell lymphoma.

Fulvestrant is also the only SERD approved for patients with breast cancer, according to the researchers.

Olaparib is a first-in-class PARP inhibitor and is the first targeted treatment to block DNA damage response in cells or tumors with a deficiency in homologous recombination repair.

Acalabrutinib is a Bruton tyrosine kinase inhibitor (BTKi) intended for the treatment of adult patients with mantle cell lymphoma who have received at least 1 prior therapy.

Timely access to cancer treatment improves patient outcomes.

The investigators said that there were no new safety signals identified, and no reported instances of tumor lysis syndrome.

As some of the nation’s leading pharmaceutical and biotech giants ramp up product development and commercialization, what was once a futuristic concept has become a reality.

Ten quiz questions to assess your knowledge on common symptoms and treatments for endometrial cancer.

Tepotinib treats adult patients with metastatic non-small cell lung cancer harboring a mesenchymal epithelial transition exon 14 skipping alteration.

Genomic analyses show promise for patients with metastatic breast cancer, reinforcing genomics as a part of the pathway of care.

Tamoxifen is given to many patients—specifically premenopausal patients—with breast cancers that express the estrogen receptor, which drives breast tumor growth.

Pyrotinib combined with capecitabine found to improve overall survival in patients with previously treated HER2-positive metastatic breast cancer.

Rylaze is a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma.